Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Withdrawn 1Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 362INDUSTRY 311NIH 45NETWORK 6OTHER_GOV 4

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Ovarian Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Esophageal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Radiotherapy 302Cisplatin 266Cyclophosphamide 230Doxorubicin 177Paclitaxel 170Vincristine 162Carboplatin 152Filgrastim 140Etoposide 139Gemcitabine 118Docetaxel 114Fluorouracil 113Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 92Leucovorin 90Gene Expression Profiling 82Granulocyte Colony-Stimulating Factor 75Specimen Handling 70Magnetic Resonance Spectroscopy 63Irinotecan 59Capecitabine 59Radiation 54Polymerase Chain Reaction 51Ifosfamide 51Rituximab 49Immunohistochemistry 49Daunorubicin 49Oxaliplatin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
NETWORK × atezolizumab × Clear all
NCT04134000 2024-05-21

BladderGATE

Fundacion Oncosur

Phase 1 Active not recruiting
40 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03281954 2024-04-08

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

NSABP Foundation Inc

Phase 3 Active not recruiting
1,550 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03357224 2024-02-22

PARCT

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Terminated
26 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT04253145 2023-11-18

Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.

Fundacion Oncosur

Phase 1/2 Unknown
184 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT02659384 2023-03-14

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
122 enrolled
Gynecologic

Ovarian Neoplasms

NCT03818997 2020-02-05

DYNAMIC

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn
Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡